Article Text

other Versions

PDF
Randomised controlled trial
Oral antiretroviral pre-exposure prophylaxis reduces the risk of HIV acquisition among men who have sex with men
  1. Marie-Claude Boily1,
  2. Benoît R Mâsse2,
  3. Dobromir Dimitrov3
  1. 1Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK
  2. 2CHU-Ste-Justine, Research Center, University of Montreal, Canada and Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
  3. 3Vaccine & Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
  1. Correspondence to Marie-Claude Boily
    Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London W2 1PG, UK; mc.boily{at}ic.ac.uk

Statistics from Altmetric.com

Commentary on:

Context

Additional interventions to combat the HIV/AIDS epidemic are needed urgently. Prevention interventions using antiretroviral agents to prevent sexually acquired HIV are being studied in humans. Current evidence suggests that, by reducing viral load to undetectable level, combination antiretroviral therapy used to treat and extend the life of HIV-infected individuals may also reduce their infectivity thereby reducing the risk of transmission to their uninfected partners.1 In 2010, a topical antiretroviral-based vaginal microbicide, Tenofovir 1% gel, was shown to reduce HIV acquisition among South African women.2 The iPrEX study is the first multicentre double-blinded randomised trial evaluating the efficacy and safety of antiretroviral drugs used as oral pre-exposure prophylaxis (PrEP) to prevent HIV infections.

Methods

The study enrolled HIV-seronegative men and transgender who have sex with men (MTSM) from 11 sites worldwide. The study drug, Emtricitabine (FTC) and Tenofovir Disoproxil Fumarate (TDF) combined in a single daily tablet (Truvada), …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.